Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2028-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 1970, the first percutaneous balloon coronary angioplasty opened a new chapter of interventional therapy. However, the incidence of intracoronary restenosis was about 30%. Subsequently, bare metal stents and drug-eluting stents (DES) reduced the incidence of in-stent restenosis (ISR) to 5%-10% and it was still a bottleneck treated by percutaneous coronary intervention (PCI). Currently, ISR is mainly treated by balloon angioplasty, stent implantation and coronary artery bypass grafting.

In 2014, the guidelines of the European Society of Cardiology recommended that drug balloon therapy (DCB) and new generation DES should be the preferred strategies for ISR treatment. Compared with DES, DCB treatment can avoid the inflammation of intima caused by multi-layer stent strut, and reduce the risk of intimal hyperplasia and thrombosis in stent. However, DCB lacks sustained radial support. Even if the residual stenosis is less than 30% after sufficient pre-dilation, the elastic retraction of the intima still exists. In addition, the antiproliferative effect of paclitaxel is significantly worse than that of sirolimus and its derivatives, and there is a lack of long-term sustained release of anti-proliferative drugs. Compared with DCB, DES can obtain long-term stable radial support and long-term anti-proliferation effect, but stent struts exposed in the vascular lumen are at risk of stent thrombosis. The new generation of DES improves the design of stent platform, improves the polymer coating, and applies new anti-proliferative drugs. It effectively reduces the inflammation of vascular wall, speeds up the process of vascular re-endothelialization, promotes early vascular repair, and significantly reduces the incidence of stent thrombosis. Recent BIOLUXRCT, RESTORE and DARE studies provide more powerful evidence for the treatment of ISR by new generation DES.

Quantitative flow ratio (QFR) is the second generation FFR detectional method based on coronary contrast image. The latest FAVOR II results also confirm that QFR is more sensitive and specific than quantitative coronary analysis (QCA) in the diagnosis of myocardial ischemia caused by coronary artery stenosis. However, there is no report of ISR treated with DCB under the guidance of QFR. The aim of this study was to evaluate the safety and efficacy of DCB in the treatment of in-stent restenosis in patients with coronary heart disease (CHD) under the guidance of QFR compared with DES implantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study )

NCT04104854

Coronary Heart Disease

NOT_YET_RECRUITING NA

The Clinical Efficacy and Safety of Drug-coated Balloon

NCT05133921

Coronary Heart Disease Angioplasty, Balloon

COMPLETED

Drug-coating Balloon Treatment in Coronary Artery Disease

NCT04255563

Coronary Artery Disease

RECRUITING

Drug-coated Balloon Therapy for In-stent Restenosis and de Novo Coronary Lesions

NCT05552911

Coronary Heart Disease

UNKNOWN

Drug Coated Balloon Only vs Drug Eluting Stent Angioplasty

NCT04482972

Coronary Artery Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current study is designed as a multicenter, randomized and prospective study aiming to evaluate the safety and efficacy of drug balloon therapy for ISR in patients with CHD under the guidance of QFR compared with DES implantation. Based on previous study reported, the incidence rate of target lesion failure is about 3% in patients with ISR undergoing DES implantation. And the design of non-inferiority study was performed in our study. Moreover, the investigators estimated 10% loss follow-up of these patients in each arm. As a result, a total of 220 patients with ISR were required, and with 110 patients per group as a ratio of 1:1 randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

drug coated balloon

A total of 110 patients with ISR are assigned to drug coated balloon treated group after randomization schedule.

Group Type EXPERIMENTAL

drug coated balloon

Intervention Type DEVICE

Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.

drug eluted stent implantation

A total of 110 patients with ISR are assigned to drug eluted stent treated group after randomization schedule.

Group Type OTHER

drug eluted stent

Intervention Type DEVICE

with regular techniques

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

drug coated balloon

Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.

Intervention Type DEVICE

drug eluted stent

with regular techniques

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

● Meet the diagnostic criteria for patients with coronary in-stent restenosis and QFR\<0.8 of target lesion in the coronary stent

Exclusion Criteria

* QFR less than 0.8, dissection above type B and thrombosis formation after pre-dilation of ISR
* Severe congestive heart failure \[LVEF \<30% or NYHA( New York Heart Association) III/IV)\]
* Severe valvular heart disease
* Life expectancy no more than 1 year or factors causing difficulties in clinical follow up
* Intolerance to aspirin and/or clopidogrel
* Known intolerance or allergy to heparin, contrast agents, paclitaxel, iopromide, rapamycin, polylactic acid-glycolic acid copolymer, Co-Cr alloy or platinum-chromium alloy
* Leukopenia or thrombopenia
* A history of peptic ulcer or GI bleeding in the previously
* Stroke within 6 months prior to the operation
* A history of severe hepatic or renal failure

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No